menu
    • menu

    Company profile for Eleusis

    NEW Drugs in Dev: 4
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Eleusis is a clinical stage life science company dedicated to unlocking the therapeutic potential of serotonin 2A receptor agonists, commonly referred to as psychedelics, through the mitigation and management of psychoactivity.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Eleusisunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    50 Grosvenor Hill, Mayfair, London W1K 3QT
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.eleusisltd.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/eleusisltd/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    euroPLX 90 Lisbon

    Not Confirmed

    envelop Contact Supplier

    euroPLX 90 Lisbon

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Eleusis Unveils World's First Legal Luxury Psychedelic Immersion
    Eleusis Unveils World's First Legal Luxury Psychedelic Immersion

    03 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/03/3231182/0/en/Eleusis-to-Debut-as-the-World-s-First-Legal-Luxury-Psychedelic-Immersion.html

    GLOBENEWSWIRE
    03 Feb 2026
    Share Share
    Consolidation in psychedelics starts as Beckley and Eleusis combine
    Consolidation in psychedelics starts as Beckley and Eleusis combine

    24 Oct 2022

    // PHARMAPHORUM

    https://pharmaphorum.com/news/consolidation-in-psychedelics-starts-as-beckley-and-eleusis-combine/

    PHARMAPHORUM
    24 Oct 2022
    Share Share
    Beckley Psytech Strengthens Pipeline With Acquisition of Eleusis Therapeutics
    Beckley Psytech Strengthens Pipeline With Acquisition of Eleusis Therapeutics

    24 Oct 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221023005029/en

    BUSINESSWIRE
    24 Oct 2022
    Share Share
    Psychedelics startup Eleusis axes SPAC deal, and more
    Psychedelics startup Eleusis axes SPAC deal, and more

    11 Jun 2022

    // Kyle LaHucik ENDPTS

    https://endpts.com/psychedelics-startup-eleusis-axes-spac-deal-but-ceo-confident-its-iv-psilocybin-therapy-will-enter-clinic-next-month/

    Kyle LaHucik ENDPTS
    11 Jun 2022
    Share Share
    Eleusis , Silver Spike Agree to Terminate Business Combination Agreement
    Eleusis , Silver Spike Agree to Terminate Business Combination Agreement

    09 Jun 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220609006021/en

    BUSINESSWIRE
    09 Jun 2022
    Share Share
    Eleusis signs $288M SPAC deal to test psychedelic depression med
    Eleusis signs $288M SPAC deal to test psychedelic depression med

    19 Jan 2022

    // Kyle LaHucik FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/eleusis-joins-cooled-off-spac-market-288m-to-bankroll-psychedelic-based-drug-for-depression

    Kyle LaHucik FIERCEBIOTECH
    19 Jan 2022
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search